Article Details

AR101 Named Orphan Drug in Europe With Trial Set to Start Mid-year - Ehlers-Danlos News

Retrieved on: 2022-03-08 04:22:36

Tags for this article:

Click the tags to see associated articles and topics

AR101 Named Orphan Drug in Europe With Trial Set to Start Mid-year - Ehlers-Danlos News. View article details on HISWAI: https://ehlersdanlosnews.com/2022/03/07/ar101-granted-orphan-drug-designation-europe-veds/

Excerpt

The European Commission has granted an orphan drug status to Aytu BioPharma's AR101 (enzastaurin), an oral therapy for Ehlers-Danlos syndrome.

Article found on: ehlersdanlosnews.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up